NCT02419170

Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC)

• Status: Withdrawn
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Washington University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to study the safety and immune response of people who receive a personalized dendritic cell vaccine with the intention of stimulating the immune system to react to lung cancer cells.

Detailed description

Tumor vaccines represent a promising area of clinical investigation in solid tumors based on evidence of clinical activity and minimal toxicity. The underlying hypothesis of this research is that immunization against tumor neoantigens is effectively required to elicit antigen-reactive T cells capable of recognizing and eliminating cancer. Moreover, both quantitative and qualitative improvements in CD8 immunity are necessary (but not sufficient) for clinical response and improved survival. The goal of this study is to build on our prior clinical trial results in melanoma by studying the immune response to tumor neoantigens in patients with stage 1 NSCLC.

Conditions

• Carcinoma, Non-Small-Cell-Lung
• Non-Small Cell Lung Cancer
• Nonsmall Cell Lung Cancer

Interventions

Type	Name	Description
PROCEDURE	Standard of care surgery
PROCEDURE	Apheresis
DRUG	Cyclophosphamide
BIOLOGICAL	Personalized mature dendritic cell vaccine

Timeline

• Start date: 2016-07-01
• Primary completion: 2019-10-01
• Completion: 2023-10-01
• First posted: 2015-04-17
• Last updated: 2016-07-18